153Curated trials
Enterprise Evidence Report · NR-REPORT-V2.0
Japan
Neuroscience Intelligence
Japan neuroscience evidence report: current clinical, research, institution and source-linked intelligence.
Evidence rank #11 of 50 · Data maturity A · Research score 43.1 · Data confidence 100.0 / 100 · Snapshot 2026-10-12 03:35 UTC.
42Recruiting trials
313Publications
257Institutions
Executive interpretation
Japan ranks #11 in the current NeuroRisk evidence-ranked market layer. This ranking summarizes indexed clinical, publication and institution evidence; it is not a probability of commercial success and not an investment recommendation.
Methodology status
Methodology NR-REPORT-V2.0. No synthetic ML confidence is presented as scientific probability. Counts and source links below are tied to the generation snapshot.
Methodology →Leading sponsors
Merck Sharp & Dohme LLC167 recruiting
Eli Lilly and Company133 recruiting
Hoffmann-La Roche92 recruiting
Pfizer71 recruiting
GlaxoSmithKline60 recruiting
Eisai Co., Ltd.60 recruiting
AbbVie51 recruiting
Biogen51 recruiting
Takeda50 recruiting
Eisai Inc.44 recruiting
Disease activity
Alzheimers33trials
Parkinsons27trials
Epilepsy18trials
Neuromuscular10trials
Depression8trials
Stroke4trials
Other Neurology4trials
Schizophrenia4trials
Adhd3trials
Migraine Headache3trials
Research institutions
Tottori UniversityOpenAlexlinked institution
National Sagamihara HospitalOpenAlexlinked institution
Kagawa Prefectural Central HospitalOpenAlexlinked institution
National Center Hospital of Neurology and PsychiatryOpenAlexlinked institution
Fukuoka Sanno HospitalOpenAlexlinked institution
Seitoku UniversityOpenAlexlinked institution
The Japanese Society of Psychiatry and NeurologyOpenAlexlinked institution
Institute for Research in Humanities, Kyoto UniversityOpenAlexlinked institution
South Osaka Neurosurgical HospitalOpenAlexlinked institution
Yamaguchi UniversityOpenAlexlinked institution
Clinical evidence trail
NCT07743580A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe DiseaseRECRUITING
NCT07684235Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)RECRUITING
NCT07589595A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)RECRUITING
NCT07291453Loving Habits: A Feasibility Study of a Support Program for Building New Parent-child Behavioral HabitsRECRUITING
NCT07227857A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic EncephalopathyRECRUITING
NCT07216703A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)RECRUITING
NCT07170150A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's DiseaseRECRUITING
NCT07033494A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)RECRUITING
NCT07011732A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)RECRUITING
Research evidence trail
PUBMEDBacterial constipation: Mucin-degrading intestinal commensal bacteria cause constipation.2026-12-31
PUBMEDBase editing rescues a hereditary motor neuron disease in mouse and patient-derived iPSC organoid models.2026-12-10
PUBMEDLongitudinal NODDI-DTI assessment of brain recovery following CPAP in obstructive sleep apnea: Tissue-compartment changes in white and gray matter.2026-12-01
PUBMEDChronotype and insomnia symptoms in the incidence and persistence of depressive symptoms: An 8-year longitudinal cohort study.2026-12-01
PUBMEDEffects of lemborexant on sleep quality and its association with morning alertness: Post hoc analysis of two phase 3 trials.2026-12-01
PUBMEDLong-term safety and efficacy of vornorexant in Japanese patients with insomnia: A 52-week open-label, randomized trial.2026-12-01
PUBMEDNeurosyphilis Concurrently Presenting With Limbic Encephalitis and Normal Pressure Hydrocephalus: A Case Report.2026-12-01
PUBMEDEffective amyloid clearance with lecanemab in a female with Alzheimer's disease: A case report.2026-12-01
PUBMEDRelation between voxel-based specific regional analysis system for Alzheimer's disease (VSRAD) on 3-tesla MRI and cognitive performances: Practical application in clinical settings.2026-12-01
PUBMEDPerceived Utility of Combining Atypical Long-Acting Injectable Antipsychotics With Psychosocial Interventions: An Exploratory Survey of Mid-Career Psychiatrists in Japan.2026-12-01
PUBMEDA case of acute lithium encephalopathy associated with elevated myelin basic protein levels in cerebrospinal fluid.2026-12-01
PUBMEDEditorial: From causal circuit mapping to clinical translation: Prefronto-thalamic hypoconnectivity in schizophrenia.2026-12-01
World Bank context
Macro indicators are shown only where a timestamped World Bank source row exists. They are context, not NeuroRisk predictions.
Sources and provenance
ClinicalTrials.gov provides NCT evidence. PubMed/NCBI and OpenAlex provide research metadata. OpenAlex links institutions. World Bank indicators are included only when an explicit source row and year exist. NeuroRisk transformations add normalization, ranking and graph connections.
Limitations
Indexed corpus counts are not guaranteed exhaustive global totals. Scores are comparative decision-support signals. This report is not medical advice, regulatory advice, patent clearance, an investment recommendation or a guarantee of outcome.